<--- Back to Details
First PageDocument Content
Monoclonal antibodies / Autoimmune diseases / Biotechnology / Immunosuppressants / Immunology / TNF inhibitor / Rheumatology / Adalimumab / Infliximab / Arthritis / Disease-modifying antirheumatic drug / Rheumatoid arthritis
Date: 2015-06-19 09:15:29
Monoclonal antibodies
Autoimmune diseases
Biotechnology
Immunosuppressants
Immunology
TNF inhibitor
Rheumatology
Adalimumab
Infliximab
Arthritis
Disease-modifying antirheumatic drug
Rheumatoid arthritis

TABLE OF CONTENTS INTRODUCTION 2

Add to Reading List

Source URL: www.abirisk.eu

Download Document from Source Website

File Size: 901,09 KB

Share Document on Facebook

Similar Documents

Large ElectronPositron Collider

Biotechnology, BS "DBEFNJD.BQ  5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT

DocID: 1xTqy - View Document

PDF Document

DocID: 1wroO - View Document

Building A Better Mousetrap: Patenting Biotechnology In The European Community

DocID: 1vr7C - View Document

BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod

DocID: 1vq6b - View Document

Biotechnology Consultation Agency Response Letter BNF

DocID: 1vpUZ - View Document